World Journal of Urology

, Volume 27, Issue 4, pp 471–476

Chemotherapy for patients with poor prognosis germ cell tumors

Topic Paper

DOI: 10.1007/s00345-009-0404-2

Cite this article as:
Riese, M.J. & Vaughn, D.J. World J Urol (2009) 27: 471. doi:10.1007/s00345-009-0404-2


Germ cell tumors (GCTs) are the most common solid malignancy in young adult males. Approximately 28% of metastatic non-seminomatous GCTs have features that confer a poor prognosis, as defined by the International Germ Cell Consensus Classification. Five-year survival rates in poor prognosis GCTs remain about 50%. Despite numerous clinical trials testing a range of approaches, four cycles of bleomycin, etoposide, and cisplatin remain the standard of care for patients with poor-risk disease. Further improvements in the outcomes of patients with poor-risk GCTs might be achieved by incorporating targeted therapies into existing regimens, and by improving our understanding of the mechanism of cisplatin insensitivity.


Testicular Germ cell Cancer Treatment Chemotherapy 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of MedicineAbramson Cancer Center, University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations